{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:45:46Z","timestamp":1789865146913,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T00:00:00Z","timestamp":1616976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T00:00:00Z","timestamp":1616976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s13760-021-01606-4","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T16:03:01Z","timestamp":1617033781000},"page":"51-57","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CLB add-on treatment in patients with epileptic encephalopathy: a single center experience with long-term follow-up"],"prefix":"10.1007","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6607-5860","authenticated-orcid":false,"given":"Dil\u015fad","family":"T\u00fcrkdo\u011fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclten","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"issue":"4","key":"1606_CR1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1528-1157.1979.tb04825.x","volume":"20","author":"H Gastaut","year":"1979","unstructured":"Gastaut H, Low MD (1979) Antiepileptic properties of clobazam, a 1\u20135 benzodiazepine, in man. Epilepsia 20(4):437\u2013444","journal-title":"Epilepsia"},{"issue":"2","key":"1606_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1600-0404.2008.01004.x","volume":"118","author":"J Riss","year":"2008","unstructured":"Riss J, Cloyd J, Gates J, Collins S (2008) Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 118(2):69\u201386","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"1606_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/0887-8994(93)90026-9","volume":"9","author":"R Munn","year":"1993","unstructured":"Munn R, Farrell K (1993) Open study of clobazam in refractory epilepsy. Pediatr Neurol 9(6):465\u2013469","journal-title":"Pediatr Neurol"},{"issue":"1","key":"1606_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/0883073812461943","volume":"28","author":"MS Perry","year":"2013","unstructured":"Perry MS, Bailey L, Malik S et al (2013) Clobazam for the treatment of intractable epilepsy in children. J Child Neurol 28(1):34\u201339","journal-title":"J Child Neurol"},{"issue":"7","key":"1606_CR5","first-page":"622","volume":"21","author":"MM Jan","year":"2000","unstructured":"Jan MM, Shaabat AO (2000) Clobazam for the treatment of intractable childhood epilepsy. Saudi Med J 21(7):622\u2013624","journal-title":"Saudi Med J"},{"issue":"4","key":"1606_CR6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.yebeh.2012.09.039","volume":"25","author":"YT Ng","year":"2012","unstructured":"Ng YT, Conry J, Paolicchi J et al (2012) Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study. Epilepsy Behav 25(4):687\u2013694","journal-title":"Epilepsy Behav"},{"issue":"2","key":"1606_CR7","first-page":"004154","volume":"16","author":"B Michael","year":"2008","unstructured":"Michael B, Marson AG (2008) Clobazam as an add-on in the management of refractory epilepsy. Cochrane Database Syst Rev 16(2):004154","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"1606_CR8","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1111\/j.1528-1157.1998.tb01444.x","volume":"39","author":"Canadian Study Group for Childhood Epilepsy","year":"1998","unstructured":"Canadian Study Group for Childhood Epilepsy (1998) Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia 39(9):952\u2013959","journal-title":"Epilepsia"},{"issue":"1","key":"1606_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0387-7604(82)80102-2","volume":"4","author":"H Shimizu","year":"1982","unstructured":"Shimizu H, Abe J, Futagi Y et al (1982) Antiepileptic effects of clobazam in children. Brain Dev 4(1):57\u201362","journal-title":"Brain Dev"},{"issue":"3","key":"1606_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1528-1157.1991.tb04670.x","volume":"32","author":"Canadian Clobazam Cooperative Group","year":"1991","unstructured":"Canadian Clobazam Cooperative Group (1991) Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Epilepsia 32(3):407\u2013416","journal-title":"Epilepsia"},{"issue":"1","key":"1606_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.nurt.2006.11.002","volume":"4","author":"YT Ng","year":"2007","unstructured":"Ng YT, Collins SD (2007) Clobazam. Neurotherapeutics 4(1):138\u2013144","journal-title":"Neurotherapeutics"},{"issue":"15","key":"1606_CR12","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1212\/WNL.0b013e318232de76","volume":"77","author":"YT Ng","year":"2011","unstructured":"Ng YT, Conry JA, Drummond R et al (2011) OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 77(15):1473\u20131481","journal-title":"Neurology"},{"issue":"4","key":"1606_CR13","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","volume":"51","author":"AT Berg","year":"2010","unstructured":"Berg AT, Berkovic SF, Brodie MJ et al (2010) Revised terminology and concepts Commission on Classification and Terminology, 2005\u20132009. Epilepsia 51(4):676\u2013685","journal-title":"Epilepsia"},{"issue":"6","key":"1606_CR14","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","volume":"51","author":"P Kwan","year":"2010","unstructured":"Kwan P, Arzimanoglou A, Berg AT et al (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia 51(6):1069\u20131077","journal-title":"Epilepsia"},{"issue":"4","key":"1606_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/epi.13671","volume":"58","author":"RS Fisher","year":"2017","unstructured":"Fisher RS, Cross H, D\u2019Souza C et al (2017) Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia 58(4):531\u2013542","journal-title":"Epilepsia"},{"key":"1606_CR16","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/j.1528-1167.2006.00607.x","volume":"47","author":"W Loscher","year":"2006","unstructured":"Loscher W, Schmidt D (2006) Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 47:1253\u20131284","journal-title":"Epilepsia"},{"issue":"3B","key":"1606_CR17","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1590\/S0004-282X2006000500001","volume":"64","author":"MR da Silveira","year":"2006","unstructured":"da Silveira MR, Mentenegro MA, Franzon RC et al (2006) Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy. Arq Neuropsiquiatr 64(3B):705\u2013710","journal-title":"Arq Neuropsiquiatr"},{"issue":"4","key":"1606_CR18","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/epi.12561","volume":"55","author":"JA Conry","year":"2014","unstructured":"Conry JA, Ng YT, Kernitsky L et al (2014) Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Epilepsia 55(4):558\u2013567","journal-title":"Epilepsia"},{"key":"1606_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.yebeh.2019.03.040","volume":"95","author":"J Hahn","year":"2019","unstructured":"Hahn J, Lee H, Kang HC et al (2019) Clobazam\u00a0as an adjunctive treatment for infantile spasms. Epilepsy Behav 95:161\u2013165","journal-title":"Epilepsy Behav"},{"key":"1606_CR20","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","volume":"356","author":"C Chiron","year":"2000","unstructured":"Chiron C, Marchand MC, Tran A et al (2000) Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome dedicated trial STICLO study group. Lancet 356:1638\u20131642","journal-title":"Lancet"},{"key":"1606_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.eplepsyres.2018.04.010","volume":"144","author":"K Nickels","year":"2018","unstructured":"Nickels K, Thibert R, Rau S et al (2018) How do we diagnose and treat epilepsy with myoclonic-atonic seizures (Doose syndrome)? Results of the Pediatric Epilepsy Research Consortium survey. Epilepsy Res 144:14\u201319","journal-title":"Epilepsy Res"},{"issue":"1","key":"1606_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejpn.2017.08.006","volume":"22","author":"B van den Munckhof","year":"2018","unstructured":"van den Munckhof B, Alderweireld C, Davelaar S et al (2018) Treatment of electrical status epilepticus in sleep: Clinical and EEG characteristics and response to treatments in 47 patients. Eur J Paediatr Neurol 22(1):64\u201371","journal-title":"Eur J Paediatr Neurol"},{"issue":"5","key":"1606_CR23","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/j.1528-1167.2008.01935.x","volume":"50","author":"JA Conry","year":"2009","unstructured":"Conry JA, Ng YT, Paolicchi JM et al (2009) Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia 50(5):1158\u20131166","journal-title":"Epilepsia"},{"issue":"1","key":"1606_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.yebeh.2017.10.003","volume":"78","author":"J Isojarvi","year":"2018","unstructured":"Isojarvi J, Gidal BE, Chung S, Wechsler RT (2018) Optimizing\u00a0clobazam\u00a0treatmentinpatientswithLennox-Gastautsyndrome. Epilepsy Behav 78(1):149\u2013154","journal-title":"Epilepsy Behav"},{"issue":"12","key":"1606_CR25","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1177\/0883073819856834","volume":"34","author":"S Gedela","year":"2019","unstructured":"Gedela S, Freedman DA, Gedela S et al (2019) Safetyandefficacyofsupratherapeuticdosesof\u00a0Clobazam. J Child Neurol 34(12):735\u2013738","journal-title":"J Child Neurol"},{"issue":"17","key":"1606_CR26","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1212\/WNL.0000000000003253","volume":"87","author":"BE Gidal","year":"2016","unstructured":"Gidal BE, Wechsler RT, Sankar R et al (2016) Deconstructing tolerance with clobazam: Post hoc analyses from an open-label extension study. Neurology 87(17):1806\u20131812","journal-title":"Neurology"},{"issue":"4","key":"1606_CR27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/j.1875-9114.2012.01028.x","volume":"32","author":"M Walzer","year":"2012","unstructured":"Walzer M, Bekersky I, Blum RA, Tolbert D (2012) Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome p450 isoenzymes. Pharmacotherapy 32(4):340\u2013353","journal-title":"Pharmacotherapy"},{"issue":"4\u20135","key":"1606_CR28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.14740\/jnr334w","volume":"5","author":"JB Renfroe","year":"2015","unstructured":"Renfroe JB, Jouko I, Lee D (2015) Somnolence and sedation were transient adverse events for most patients receiving clobazam therapy: post hoc analysis of trial OV-1012 data. J Neurol Res 5(4\u20135):252\u2013256","journal-title":"J Neurol Res"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-021-01606-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-021-01606-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-021-01606-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T14:29:45Z","timestamp":1646317785000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-021-01606-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,29]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1606"],"URL":"https:\/\/doi.org\/10.1007\/s13760-021-01606-4","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,29]]},"assertion":[{"value":"6 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national guidelines on human experimentation and has been approved by the appropriate committees at our institution (indicated in the manuscript).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients and\/or parents\/caregiver(s) provided written informed consent and\/or assent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participitate"}},{"value":"Present.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}